Skip to main content

Table 1 Baseline patient characteristics, pre-implant hospitalizations, and disposition

From: The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach

 

NON infected

Infected

P

Total

43

67

 

Sex % FEMALE

18.6

34.3

0.06

Age (Mean, SD, IQR)

60.6, 12.4, 17

62.9, 10.4, 13

0.29

Race

   

 Caucasian%

72.1

67.2

0.59

 Black%

16.3

19.4

0.68

 Hispanic%

0

1.5

0.42

 Asian%

2.3

1.5

0.76

 Native American%

0

3

0.25

 Other Race%

4.7

7.5

0.56

 Unknown/Refused%

4.7

0

0.07

Ethnicity

   

 Non-Hispanic%

86

88.1

0.75

 Cuban%

0

1.5

0.42

 Puerto Rican%

2.3

4.5

0.54

 Spanish%

2.3

1.5

0.76.

 Unknown/Refused%

9.3

4.5

0.32

Mood Disorder %

16.3

31.3

0.08

INTERMACS (Mean, SD)

2.2, 1.0

2.4, 0.9

0.27

BMI (Mean, SD)

28.5, 6.9

30.5, 6.6

0.13

Renal Failure (%)

30.2

40.3

0.28

DM %

55.8

53.7

0.83

Immunocompromise %

9.3

7.5

0.74

Balloon Pump %

65.1

46.3

0.06

Impella %

23.3

22.4

0.91

Smoker %

19.0

27.3

0.33

Pacemaker%

71.4

65.7

0.53

No. Admissions prior to Implant

56

135

 

 Mean LOS/admission (SD)

6.8 d (4.9)

8.9 d (10.2)

 

 Total days

381

1,202

 

 Mean Total LOS/patient (SD)

8.9 d 4.9

17.9 d 10.2

0.0001

Mean Initial Implant Adm. Duration (SD)

33.6 d (27.1)

38.1 d (36.1)

0.49

Guideline Congruent Abx. Prophylaxis (%)

77.0

89.1

0.17

Disposition post implant

   

 Rehabilitation facility

18 (41%)

46 (69%)

0.004

 Home

17 (40%)

17 (25%)

0.09

 Died in hospital

8 (19%)

4 (6%)

0.03

  1. * Immunocompromised was defined as those patients whose immune mechanisms are deficient because of immunologic disorders (e.g., human immunodeficiency virus [HIV] infection, congenital immune deficiency syndrome, cancer not in remission, or immunosuppressive therapy (e.g., radiation, cytotoxic chemotherapy, anti-rejection medication, or prednisone dose equivalent to ≥ 2 mg/kg of body weight or ≥ 20 mg/day administered for ≥ 14 consecutive days. If a patient had any of these, they were classified as immunosuppressed